TY - JOUR
T1 - Paradoxic elevation of fibrinopeptide A after streptokinase
T2 - Evidence for continued thrombosis despite intense fibrinolysis
AU - Eisenberg, Paul R.
AU - Sherman, Laurence A.
AU - Jaffe, Allan S.
PY - 1987
Y1 - 1987
N2 - Elevated levels of fibrinopeptide A, a marker of thrombin activity associated with acute myocardial infarction, have been found to decrease after administration of streptokinase when reperfusion occurs. In contrast, in patients without reperfusion and those with reocclusion after streptokinase therapy, fibrinopeptide A remains elevated. In the present study early serial measurements of fibrinopeptide A were used to further characterize this paradoxic increase in thrombin activity after streptokinase and to characterize its response to heparin. In 19 patients with acute myocardial infarction fibrinopeptide A was elevated to 82.3 ± 43.5 ng/ml (mean ± SE) before therapy. Thirty minutes after the initiation of streptokinase, fibrinopeptide A increased to 300.1 ± 117.4 ng/ml (p < 0.01), consistent with extensive thrombin activity. Fibrinopeptide A remained elevated until 15 minutes after a heparin bolus injection when levels decreased to 15% of the postStreptokinase value (49.2 ± 13.3 ng/ml) (p < 0.001). These data document a prompt paradoxic increase in thrombin activity after administration of streptokinase that may be responsible for failure of therapy in some patients.
AB - Elevated levels of fibrinopeptide A, a marker of thrombin activity associated with acute myocardial infarction, have been found to decrease after administration of streptokinase when reperfusion occurs. In contrast, in patients without reperfusion and those with reocclusion after streptokinase therapy, fibrinopeptide A remains elevated. In the present study early serial measurements of fibrinopeptide A were used to further characterize this paradoxic increase in thrombin activity after streptokinase and to characterize its response to heparin. In 19 patients with acute myocardial infarction fibrinopeptide A was elevated to 82.3 ± 43.5 ng/ml (mean ± SE) before therapy. Thirty minutes after the initiation of streptokinase, fibrinopeptide A increased to 300.1 ± 117.4 ng/ml (p < 0.01), consistent with extensive thrombin activity. Fibrinopeptide A remained elevated until 15 minutes after a heparin bolus injection when levels decreased to 15% of the postStreptokinase value (49.2 ± 13.3 ng/ml) (p < 0.001). These data document a prompt paradoxic increase in thrombin activity after administration of streptokinase that may be responsible for failure of therapy in some patients.
UR - http://www.scopus.com/inward/record.url?scp=0023245001&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023245001&partnerID=8YFLogxK
U2 - 10.1016/S0735-1097(87)80194-8
DO - 10.1016/S0735-1097(87)80194-8
M3 - Article
C2 - 3624659
AN - SCOPUS:0023245001
SN - 0735-1097
VL - 10
SP - 527
EP - 529
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 3
ER -